Artelo Biosciences Reports $5.4 Million Net Loss and Increased Cash Reserves in Latest 10-Q Filing

Artelo Biosciences, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $5.4 million for the first half of 2026, a slight improvement from a loss of $5.6 million during the same period in 2025. Total operating expenses decreased to $5.2 million from $5.5 million year-over-year, primarily due to reduced research and development costs, which fell to $1.6 million from $3.3 million. General and administrative expenses increased to $3.5 million from $2.3 million, reflecting higher professional fees and employee compensation.

The company experienced a notable increase in cash reserves, with cash and cash equivalents rising to $4.2 million as of June 30, 2026, compared to $600,000 at the end of 2025. This increase was largely attributed to a successful private placement offering that generated approximately $10 million in net proceeds, which will be utilized for working capital and debt repayment. The total assets of Artelo Biosciences also grew significantly to $6.5 million from $2.8 million at the end of the previous fiscal year.

Strategically, Artelo has made several key moves, including the issuance of common stock and warrants as part of its financing efforts. The company entered into a securities purchase agreement on March 27, 2026, which involved the sale of 81,000 shares of common stock at $3.45 per share, along with pre-funded warrants and common warrants. Additionally, the company has established an at-the-market equity program allowing it to sell up to $6.5 million in shares over time. These initiatives are part of Artelo's broader strategy to enhance liquidity and support ongoing research and development activities.

Operationally, Artelo has not generated any revenue since its inception and continues to focus on developing therapeutics targeting lipid-signaling pathways. The company has consolidated its operations across its subsidiaries in Ireland, the UK, and Canada. As of June 30, 2026, the total number of common shares outstanding increased to 4.2 million from 673,008 shares at the end of 2025, reflecting the impact of recent equity financing activities. The company’s employee headcount has also increased, aligning with its expanded operational needs.

Looking ahead, Artelo Biosciences faces challenges in securing additional funding to sustain its operations, as indicated in its filing. The company has expressed the need to raise further capital through equity or debt offerings within the next twelve months. The ongoing global economic uncertainties, including inflation and geopolitical tensions, may impact the company’s ability to achieve its financial and operational goals. Artelo remains focused on advancing its clinical programs while navigating these challenges.